Topic: amyotrophic lateral sclerosis
Neurimmune's antibody targets the misfolded SOD1 protein that has been implicated in a subset of ALS cases.
Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
VistaGen Therapeutics has licensed Pherin Pharmaceuticals' lead candidate, a nasal spray for social anxiety disorder.
Swedish researchers have found that the rogue SOD1 protein can “transmit” protein misfolding in ALS.
PARP inhibitors prevent the misplacement of a specific protein that has been implicated in ALS, new research shows.
Blocking a pathway that causes healing cells to turn bad could offer a new way to treat neurological disorders.
Biogen has bolted on a couple of early-stage drug candidates for neuromuscular diseases via a $535 million deal with California startup AliveGen.
Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
BrainStorm will not provide its ALS treatment under right-to-try because it could not secure funding for all patients.
Flex Pharma is considering a sale or merger to keep afloat. In the meantime, it has scrapped two midstage trials and is cutting its workforce by 60%.